Related Experiment Videos
Solitary spinal plasmacytomas: management and outcome
M M Poor1, P W Hitchon, C E Riggs
1Division of Neurosurgery, University of Iowa Hospitals and Clinics, Iowa City 52242.
Journal of Spinal Disorders
|January 1, 1988
Summary
Solitary plasmacytoma of the spine has a 50% progression rate to multiple myeloma. Early diagnosis and treatment of solitary spinal plasmacytoma are crucial for patient survival and prognosis.
Area of Science:
- Oncology
- Neoplastic Diseases
Background:
- Solitary plasmacytoma is a rare plasma cell neoplasm.
- Spinal solitary plasmacytoma requires careful management due to potential progression.
Purpose of the Study:
- To evaluate the clinical course and outcomes of patients with solitary plasmacytoma of the spine.
- To identify factors influencing progression to multiple myeloma.
Main Methods:
- Retrospective review of nine patients diagnosed with solitary plasmacytoma of the spine.
- Analysis of patient demographics, clinical presentation, treatment modalities, and survival data.
Main Results:
- Four out of nine patients (44%) progressed to multiple myeloma within 9 months.
- Patients progressing to multiple myeloma had a median survival of 23 months.
- The remaining five patients, free of systemic disease, survived a median of 78 months.
- No correlation found between age, lesion location, symptoms, lab results, surgery, or radiation and disease progression.
Conclusions:
- Approximately 50% of solitary spinal plasmacytoma cases progress to systemic multiple myeloma.
- Long-term survival is achievable for patients without systemic progression following local treatment.
- Prognosis is significantly poorer for patients who develop multiple myeloma.